创新药热情回归，重视礼来口服减肥药产业链机会！

Investment Rating - The industry rating is "Outperform the Market" [7][70] Core Insights - The enthusiasm for innovative drugs is returning, with a focus on investment opportunities in the Eli Lilly oral weight loss drug supply chain [3][5] - Eli Lilly's oral weight loss drug Orforglipron is expected to receive FDA approval in April 2026, which is a key catalyst for the industry [5][19] - The report emphasizes the importance of innovative drugs and medical devices as the main themes for the pharmaceutical industry in 2026, with a focus on revenue realization and high-growth performance [6][30] Summary by Sections 1. Weekly Performance of Recommended Pharmaceutical Portfolio - The recommended portfolio outperformed the pharmaceutical index by 4.9 percentage points and the overall market by 7.8 percentage points [14][15] 2. Eli Lilly's Oral Weight Loss Drug Orforglipron Approval - Orforglipron has shown superior results in the ACHIEVE-3 study compared to oral semaglutide, with significant improvements in A1C reduction and weight loss [20][21] - The drug is expected to be launched in 2026, with a focus on investment opportunities in the supply chain, including companies like WuXi AppTec and Kelun Pharmaceutical [5][25] 3. Weekly Market Review and Hotspot Tracking (March 23-27, 2026) - The CITIC Pharmaceutical Index fell by 1.4% but outperformed the CSI 300 Index by 2.9 percentage points [4][30] - The top-performing stocks included Meinuohua (+40.7%), Wanbangde (+38.8%), and Fuxiang Pharmaceutical (+27.6%) [43][49] - The report highlights the recovery of innovative drug sentiment and the expected significant returns in the upcoming months due to upcoming conferences and strong revenue growth [6][30]